SecBot SecBot
PRESS-RELEASE ·Filed Nov 4, 2026

CTKB

Cytek Biosciences, Inc.
NEUTRAL
Impact 4/10
Horizonweeks Processed12d 8h ago WireGlobeNewswire
Press release · Earnings
Actionable Insight • Neutral

Monitor Q4 2026 results for revenue acceleration and whether gross margin improvement sustains. The narrowed guidance range suggests management sees limited upside to the full-year outlook. Watch for updates on the patent litigation post-verdict motions.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5
Entry
$5.40
T+0 close · Nov 4, 2026 · via day close
Latest settled
+2.22%
T+5 · $5.52 · next T+20 in 17d
Vs SPY
−1.07%
α at T+5
Latest observation
+7.46%
T+6 · FF3 residual α
  1. T+0 · Nov 5 $5.40entry
  2. T+1 · 11d ago +7.96%α +7.65% · $5.83
  3. T+5 · 5d ago +2.22%α −1.07% · $5.52
  4. T+7 · todayOpen
  5. T+20 · in 17d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Cytek Biosciences reported Q3 2026 revenue of $53.2M, slightly above the $52.9M consensus, but GAAP EPS of -$0.05 beat the -$0.07 estimate. Revenue grew only 2% YoY, and adjusted EBITDA fell sharply to $0.7M from $2.5M a year ago. The company narrowed full-year revenue guidance to $208M-$211M, maintaining the midpoint, while gross margin improved 590 bps to 59%.

Key Financial Metrics

EPS
−$0.05
est −$0.07 · +28.6%
Revenue
$53.2M
est $52.9M · +0.6% · +1.8% YoY
Rating
beat
Guidance
$208M-$211M
maintained
Gross Margin
59%

Key Facts

  • Q3 2026 total revenue $53.2M, +2% YoY vs $52.3M
  • GAAP EPS -$0.05 vs consensus -$0.07 (beat)
  • GAAP gross margin 59%, up 590 bps YoY from 53%
  • Adjusted EBITDA $0.7M vs $2.5M in Q3 2025
  • Full-year 2026 revenue guidance narrowed to $208M-$211M, midpoint maintained
  • Recurring revenue (trailing 12-month) 36% of total, up from 33%
  • Installed base grew by 140 units to 4,073
  • U.S. revenue grew 12% YoY; high-end instrument revenue up 11%
  • Net loss $6.1M vs $5.5M in Q3 2025
  • Cash & securities $256.3M, down $5.7M from Q2 2026

Financial Impact

Revenue slightly above consensus; EPS beat by $0.02; adjusted EBITDA declined $1.8M YoY

revenueepsgross marginadjusted ebitda

Segment Breakdown

SegmentRevenueGrowth
Product$37.2M-2.5%
Service$16.1M+13.3%

Risk Factors

  • Revenue growth decelerated to 2% YoY, well below prior quarters
  • Adjusted EBITDA declined sharply despite gross margin expansion
  • Net loss widened YoY; operating cash flow not disclosed
  • Litigation expenses weighing on G&A; post-verdict motions and potential appeal create uncertainty
  • Full-year guidance midpoint implies Q4 revenue of ~$55M-$58M, requiring acceleration from Q3's $53.2M

Market Snapshot

Exchange
Nasdaq
Sector
Laboratory Analytical Instruments
Analyst Consensus
70% bullish (10 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3395793

Track record

14 reports on CTKB

Performance horizon

1 of 3 bullish or bearish reports moved the stock their way by T+1. Best: +1.49% at T+1 after the Jun 11, 2026 report. 1 of 3 went positive at some point.

Filters
  1. Nov 16, 20261d ago ITC Section 337 Neutral 3/10 Entry $5.78 Now $5.63 −2.60% settles Nov 18
  2. Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $5.84 to $5.63 Now $5.63 −3.60% ▼ −3.60% −1.68% vs SPY
  3. Nov 10, 20266d ago Institutional Cluster Bullish 4/10 Entry $5.79 to $5.76 Now $5.63 −2.76% ▼ −0.52% −1.84% vs SPY
  4. Nov 4, 202612d ago 8-K Neutral 4/10 No price data
  5. Nov 4, 202612d ago Press Release Neutral 4/10 Viewing Entry $5.40 to $5.83 Now $5.63 +4.26% ▲ +7.96% +7.65% vs SPY
  6. Nov 3, 202613d ago SC 13G/A Neutral 2/10 Entry $5.88 to $5.40 Now $5.63 −4.25% ▼ −8.16% −3.75% vs SPY
  7. Oct 21, 202626d ago Press Release Neutral 1/10 Entry $5.43 to $5.59 Now $5.63 +3.68% ▲ +2.95% +3.47% vs SPY
  8. Sep 22, 20267w ago Institutional Cluster Mixed 4/10 Entry $5.71 to $5.68 Now $5.63 −1.40% ▼ −0.53% +0.19% vs SPY
  9. Aug 24, 202612w ago 8-K Bearish 7/10 Entry $4.44 to $4.58 Now $5.63 −26.80% ▼ −3.15% −2.83% vs SPY
  10. Jun 25, 202620w ago 8-K Neutral 2/10 Entry $4.48 to $4.34 Now $5.63 +25.67% ▼ −3.13% −4.77% vs SPY
Showing 10 of 14

US Market Status

Market Closed · Opens in 9h

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 4, 2026